Core Insights - The company achieved total revenue of 574 million RMB in 2025, driven by strong commercialization growth [1] - The first commercial product, Nairike (Aorebatin), saw significant sales growth of 435 million RMB, an increase of 81% year-on-year [1] - The second product, Lishengtuo (Lisatrakra), generated sales of 70.58 million RMB within five months of its approval in July 2025 [1] - The company reported a total cash position of approximately 2.47 billion RMB, indicating improved cash flow [1] Global Clinical Development - The company achieved milestone breakthroughs with global Phase III studies for Nairike in treating Ph+ ALL and Lishengtuo for high-risk MDS, both receiving approvals from the FDA and EMA in 2025 [1] - Multiple Phase III clinical studies are currently underway globally, with four studies having received FDA and EMA approvals [1] Commercialization and Team Expansion - The commercialization team expanded rapidly, exceeding 270 personnel by the end of 2025, covering over 1,500 hospitals nationwide [2] - The company successfully listed on NASDAQ in January 2025, becoming the first biopharmaceutical company to have a dual primary listing in Hong Kong and the U.S. [2] Strategic Vision - The CEO emphasized that 2025 was a pivotal year for the company's global expansion, achieving breakthroughs in commercialization, clinical development, pipeline innovation, and capital markets [2] - The company aims to focus on unmet patient needs and accelerate global clinical development of core products, aspiring to become a global leader in the field of hematologic oncology innovation [2]

Core Insights - The company achieved its first annual profit since its establishment in 2025, with total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, reversing a loss of 4.978 billion yuan from the previous year [1][2] Financial Performance - Total revenue reached 38.205 billion yuan, up 40.4% from 27.214 billion yuan in the previous year [2] - Product revenue was 37.770 billion yuan, reflecting a 39.9% increase from 26.994 billion yuan [2] - Operating profit was 2.562 billion yuan, while total profit was 2.558 billion yuan, both transitioning from losses in the previous year [2] - Basic earnings per share improved from -3.64 yuan to 1.00 yuan [2] - The weighted average return on equity was 5.19%, recovering from -20.20% [2] Product Performance - The core product, Baiyueze® (Zebutinib), generated global sales of 28.067 billion yuan, a 48.8% increase, accounting for 73.5% of total revenue [3][5] - Sales in the U.S. market reached 20.206 billion yuan, up 45.5%, while European sales were 4.265 billion yuan, increasing by 66.4% [5] - Other product segments, including Bai Ze An® and licensed products from Amgen, contributed significantly, with total product revenue reaching 37.770 billion yuan, making up 98.9% of total revenue [6] Cash Flow and Assets - The company reported a significant increase in operating cash flow, with free cash flow reaching 9.42 billion yuan [7] - Total assets grew to 57.423 billion yuan, a 34.1% increase from the beginning of the period, while equity attributable to shareholders rose to 30.601 billion yuan, up 26.6% [7] Research and Development - R&D expenses for 2025 were 21.46 billion yuan, a 10% increase, but the proportion of R&D spending relative to revenue decreased to 40.4% [3][8] - The company has invested over 56 billion yuan in R&D since its inception, with 14.14 billion yuan spent in 2024 alone [3] Capital Structure and Shareholder Changes - Hillhouse Capital, a cornerstone investor, has reduced its stake from 8.97% to 4.89% through two rounds of share sales in 2025, cashing out approximately 7.146 billion HKD [4] - Other shareholders, including Amgen and Baker Brothers Life Sciences, maintained their holdings, while new investors have entered the shareholder base [4]

Core Viewpoint - The stock price of Peijia Medical-B (02565.HK) fell by 5.54% to HKD 63.05 on February 13, primarily due to a combination of market weakness, profit-taking after index inclusion, technical pressure, funding discrepancies, and high valuation concerns [1][5]. Stock Performance - On February 13, the Hang Seng Index dropped by 1.72%, and the biotechnology sector declined by 0.95%, indicating increased risk aversion in the market, leading to capital outflows from growth sectors like pharmaceuticals [2]. Reasons for Stock Price Movement - Peijia Medical-B was announced to be included in the Hang Seng Composite Index effective March 9, 2026. However, this positive news was partially anticipated by the market, as the stock had already risen approximately 4.7% over February 11 and 12. On February 13, the stock opened high but fell after reaching a peak of HKD 67.40, suggesting profit-taking by some investors [3]. Funding and Technical Analysis - The closing price of HKD 63.05 on February 13 was below both the 5-day moving average (HKD 65.27) and the 20-day moving average (HKD 65.515). The MACD histogram, while positive, remained below the zero line, indicating a bearish short-term trend. The stock experienced a volatility of 9.51%, with a low of HKD 61.05, near the lower Bollinger Band (HKD 58.974), reflecting strong selling pressure. Although there was a net inflow of HKD 335.67 million, it was primarily driven by retail investors, with institutional investors showing a cautious stance [4]. Company Valuation - As of February 13, the company's trailing twelve months (TTM) price-to-earnings ratio was -101.56, and the price-to-book ratio was 42.84, indicating a high valuation level. The company’s R&D expenditure for the mid-2025 period was HKD 26.294 million, suggesting significant ongoing investment pressure. Market concerns may arise regarding the alignment of its earnings outlook with current valuation levels [5].

Core Insights - The company, Nocera Biopharma-U (688428), is making significant progress in clinical research, partnerships, and product commercialization in 2026. Clinical Development Progress - ICP-488 (highly selective TYK2 inhibitor) has completed patient enrollment for its Phase III clinical trial for psoriasis, with a total of 383 patients enrolled, marking a key clinical milestone [2] - Soficitinib (TYK2 inhibitor) has completed patient enrollment for its Phase III registration trial for moderate to severe atopic dermatitis, with accelerated trials for indications like vitiligo and nodular prurigo [2] - Obinutuzumab (BTK inhibitor) has completed its Phase III clinical study for idiopathic thrombocytopenic purpura (ITP) and is expected to submit a New Drug Application (NDA) in the first half of 2026; a Phase IIb study for systemic lupus erythematosus (SLE) has met its primary endpoint, with a Phase III trial set to begin soon [3] - BCL2 inhibitor (Mesutoclax/ICP-248) is advancing two registration Phase III clinical studies in the hematological malignancies field [3] Collaboration and International Expansion - The partnership with Zenas BioPharma, established in October 2025, plans to initiate a global Phase III clinical trial for Obinutuzumab targeting secondary progressive multiple sclerosis (SPMS) in the first quarter of 2026; Zenas will also advance two preclinical molecules from Nocera Biopharma into clinical stages in 2026. The total potential value of this collaboration exceeds $2 billion, including milestone payments and royalties [4] Commercialization and Product Pipeline - Newly approved drugs, Tansimod (Mingnuokai) and Zolbetuximab (Yinuoxin), which were approved in 2025, are now on the market and expected to contribute to revenue growth alongside Obinutuzumab. The new indications for Obinutuzumab (such as first-line treatment for CLL/SLL) are anticipated to drive continued sales growth [5] - The company achieved profitability for the first time in 2025, with revenue of approximately 2.37 billion yuan and a net profit of about 630 million yuan. Management indicates that the company will enter a phase of sustainable profitability starting in 2025, focusing on global expansion and pipeline diversification to solidify performance [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ( 於開曼群島註冊成立的有限公司 ) ( 股份代號 : 9939) 自願公告 就防脫泡沫劑產品簽訂獨家銷售代理協議 本公告由開拓藥業有限公司*（「 本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以知會本公司股東及潛在投資者有關本集團的最新進展。 銷售代理協議 本公司董事（「董事」）會（「 董事會」）欣然宣佈，於二零二六年一月二十一日 （交易時段後），本公司全資附屬公司開禧香港有限公司（「開禧香港」）與北京德 開醫藥科技有限公司（「德開醫藥」）訂立獨家銷售代理協議（「銷售代理協議」）， 內容有關本公司防脫泡沫劑產品在中國內地市場的銷售代理及市場推廣（「業務合 作」）。 根據銷售代理協議，開禧香港與德開醫藥就本公司防脫泡沫劑產品在中國內地市場的 銷售代理及市場推廣達成共識。雙方依託各自優勢與資源，建立密切合作關係，共同 推動業務發展和產品延伸，實現優勢互補，協同發展。 - 1 - 開拓藥業有限公司 ＊ ...

Group 1 - The company is actively promoting the sales of amino acid surfactants and pyrrolidone ethanolamine salts, having entered the supply chains of leading brands such as Unilever [1] - The commercialization of P-S products in the U.S. market is pending FDA approval [1] - The impact of inventory reduction for sunscreen products is gradually diminishing, with varying recovery situations for different products [1] Group 2 - An investor inquired about the expansion of amino acid surfactants into head brands over the past two years and the addition of new head clients for the anti-dandruff agent, specifically asking about supply volume and production capacity utilization [3] - Questions were raised regarding the bulk supply of PS sunscreen agents to American brands and the recovery of supply volume in collaboration with DSM to 2022 levels [3] - The investor also inquired about the expected operational status of the Malaysian factory by April 2026 and the addition of new clients for overseas exhibitions in 2025 [3]

Core Insights - The article emphasizes the emergence of "future unicorns," companies that are on the verge of significant growth and transformation, rather than focusing solely on established unicorns [2] - The "Entrepreneurship 100" list aims to identify businesses that will drive commercial change over the next 3-5 years, having supported 1,295 high-growth companies over 16 years, with 191 achieving unicorn status [2] - The 2025 list reveals a surge in AI companies, with a 52% year-on-year increase, and highlights that 70% of the listed companies have achieved global expansion [2] Group 1: Market Trends - The average valuation of the listed companies is 2.571 billion yuan, with 61% having completed five or more funding rounds [25] - 95% of the companies have initiated international expansion, with 72% entering the European market [21][22] - The AI sector has seen a significant increase, with 35 companies listed, marking a 52% growth from the previous year [16] Group 2: Commercialization and Financial Performance - 83% of the products from the listed companies have been launched, with 51% having completed the full cycle from listing to scaling [18] - 93% of the companies have started monetizing their products, with 50% experiencing rapid revenue growth [18] - The total historical financing for the listed companies amounts to 64.41 billion yuan, with an average of 5.5 funding rounds per company [25] Group 3: Investment Landscape - The proportion of companies in the A-round funding stage has increased to 40%, with 92 companies completing new funding rounds [27] - Shunxi Fund has emerged as the top investor, backing 15 companies, followed by several other prominent funds [27][29] - The distribution of valuations shows that 33 companies have valuations exceeding 3 billion yuan, with 4 nearing unicorn status at 6 billion yuan or more [25]

復䢇醫療科技有限公司* Sisram Medical Ltd 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 於本公告日期，本公司董事會成員包括執行董事Lior Moshe DAYAN先生及李家 宏先生；非執行董事劉毅先生、馮蓉麗女士及Caroline Xiaokui JIN女士；獨立非 執行董事方香生先生、陳志峰先生、陳怡芳女士及廖啟宇先生。 （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司欣然宣佈旗下獲再授權注射用A型肉毒毒素（DaxibotulinumtoxinA-lanm， 中國境內商標達希斐®，英文商標DAXXIFY®，項目代號RT002，以下簡稱「達希 斐」）已通過中華人民共和國（「中國」）食品藥品檢定研究院質量標準檢驗。該產品 適用於暫時性改善成人因皺眉肌和╱或降眉間肌活動引起的中度至重度眉間紋。 截至本公告發佈之日，於中國境內尚 ...

Core Insights - Google co-founder Sergey Brin reflected on the failure of Google Glass, admitting that he was overly confident and rushed the product to market before it was ready [1][3] Group 1: Product Launch and Market Reception - Google Glass was introduced to a limited number of users in 2012, quickly becoming a well-known product despite not being the first of its kind [1] - The product faced immediate commercial failure due to its awkward design, privacy concerns from the 5-megapixel camera, and a high price point of $1,500, equivalent to approximately $2,120 today [3] Group 2: Lessons Learned - Brin emphasized the importance of waiting for a product to mature before launching it publicly, regardless of how innovative the idea may be [3] - The experience of Google Glass parallels Apple's earlier failure with the Newton handheld computer, which was also ahead of its time and priced too high for market acceptance [3]

Core Viewpoint - Weichai Power (000338) expresses confidence in the market potential and application areas of SOFC products, emphasizing its commitment to commercializing these products in response to global customer needs [1] Group 1 - The company highlights the broad market prospects for SOFC products [1] - The company plans to leverage its strong technological foundation to meet market trends [1] - The company aims to continue advancing the mass commercialization of SOFC products [1]